Literature DB >> 12972306

Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer.

Naoya Kakimoto1, Takehiro Inoue, Toshihiko Inoue, Shumei Murakami, Souhei Furukawa, Ken Yoshida, Yasuo Yoshioka, Hideya Yamazaki, Eiichi Tanaka, Kimishige Shimizutani.   

Abstract

PURPOSE: To evaluate the treatment results of low-dose-rate (LDR) and high-dose-rate (HDR) interstitial brachytherapy (ISBT) for T3 mobile tongue cancer.
MATERIAL AND METHODS: Between 1974 and 1992, 61 patients with T3 mobile tongue cancer were treated with LDR ISBT using (192)Ir hairpins with or without single pins. In addition, between 1991 and 1999, 14 patients were treated with HDR ISBT. For nine patients treated with ISBT alone, the total dose was 59-94 Gy (median 72 Gy) within one week in LDR ISBT and 60 Gy/10 fractions/5 days in HDR ISBT. For 66 patients treated with a combination therapy of external beam radiotherapy (EBRT) and ISBT, the total dose was 12.5-60 Gy (median 30 Gy) of EBRT and 50-112 Gy (median 68 Gy) within 1 week in LDR ISBT or 32-60 Gy (median 48 Gy)/8-10 fractions/5-7 days in HDR ISBT.
RESULTS: The 2- and 3-year local control rates of all patients were both 68%. The 2- and 3-year local control rates of patients treated with LDR ISBT were both 67%, and those with HDR ISBT were both 71%. The local control rate of patients treated with HDR ISBT was similar to those with LDR ISBT.
CONCLUSIONS: ISBT for T3 mobile tongue cancer is effective and acceptable. The treatment result of HDR ISBT is almost similar to that of LDR ISBT for T3 mobile tongue cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972306     DOI: 10.1016/s0167-8140(03)00055-0

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  13 in total

Review 1.  The role of brachytherapy in the treatment of squamous cell carcinoma of the head and neck.

Authors:  Małgorzata Wierzbicka; Anna Bartochowska; Vratislav Strnad; Primož Strojan; William M Mendenhall; Louis B Harrison; Alessandra Rinaldo; Puja Sahai; Susanne Wiegand; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-22       Impact factor: 2.503

2.  Age is not a limiting factor for brachytherapy for carcinoma of the node negative oral tongue in patients aged eighty or older.

Authors:  Hideya Yamazaki; Ken Yoshida; Tadayuki Kotsuma; Yasuo Yoshioka; Masahiko Koizumi; Souhei Furukawa; Naoya Kakimoto; Kimishige Shimizutani; Tsunehiko Nishimura
Journal:  Radiat Oncol       Date:  2010-12-09       Impact factor: 3.481

3.  Adjuvant brachytherapy for oral squamous cell carcinomas: a single-center experience comparing low-dose and pulsed-dose-rate techniques.

Authors:  Pierre Mattei; Emilien Chabrillac; Bastien Cabarrou; Agnès Dupret-Bories; Sébastien Vergez; Jérôme Sarini; Raphaël Lopez; Lucie Piram; Thomas Brun; Anouchka Modesto
Journal:  Strahlenther Onkol       Date:  2021-11-16       Impact factor: 3.621

4.  High-dose-rate interstitial brachytherapy for mobile tongue cancer: preliminary results of a dose reduction trial.

Authors:  Hironori Akiyama; Ken Yoshida; Hideya Yamazaki; Tadashi Takenaka; Tadayuki Kotsuma; Koji Masui; Yasuo Yoshioka; Takumi Arika; Kimishige Shimizutani; Eiichi Tanaka
Journal:  J Contemp Brachytherapy       Date:  2014-02-19

5.  Clinical outcome of high-dose-rate interstitial brachytherapy in patients with oral cavity cancer.

Authors:  Sung Uk Lee; Kwan Ho Cho; Sung Ho Moon; Sung Weon Choi; Joo Yong Park; Tak Yun; Sang Hyun Lee; Young Kyung Lim; Chi Young Jeong
Journal:  Radiat Oncol J       Date:  2014-12-30

Review 6.  High-dose-rate and pulsed-dose-rate brachytherapy for oral cavity cancer and oropharynx cancer.

Authors:  Alfredo Polo
Journal:  J Contemp Brachytherapy       Date:  2010-01-13

7.  Dose reduction trial from 60 Gy in 10 fractions to 54 Gy in 9 fractions schedule in high-dose-rate interstitial brachytherapy for early oral tongue cancer.

Authors:  Hironori Akiyama; Ken Yoshida; Kimishige Shimizutani; Hideya Yamazaki; Masahiko Koizumi; Yasuo Yoshioka; Naoya Kakimoto; Shumei Murakami; Souhei Furukawa; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2012-06-28       Impact factor: 2.724

Review 8.  High dose rate brachytherapy for oral cancer.

Authors:  Hideya Yamazaki; Ken Yoshida; Yasuo Yoshioka; Kimishige Shimizutani; Souhei Furukawa; Masahiko Koizumi; Kazuhiko Ogawa
Journal:  J Radiat Res       Date:  2012-11-23       Impact factor: 2.724

9.  High dose rate versus low dose rate brachytherapy for oral cancer--a meta-analysis of clinical trials.

Authors:  Zhenxing Liu; Shengyun Huang; Dongsheng Zhang
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

10.  Preventing Complications from High-Dose Rate Brachytherapy when Treating Mobile Tongue Cancer via the Application of a Modular Lead-Lined Spacer.

Authors:  Shumei Murakami; Rinus G Verdonschot; Naoya Kakimoto; Iori Sumida; Masateru Fujiwara; Kazuhiko Ogawa; Souhei Furukawa
Journal:  PLoS One       Date:  2016-04-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.